Skip Navigation

Neuro-Oncology 2001 3(3):201-210; doi:10.1093/neuonc/3.3.201
© 2001 by Society
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Visted, T.
Right arrow Articles by Enger, P. O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Visted, T.
Right arrow Articles by Enger, P. O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 by the Society forNeuro-Oncology

Cell encapsulation technology as a therapeutic strategy for CNSmalignancies

Therese Visted2, Rolf Bjerkvig and Per Øyvind Enger

Laboratory of Neuro-Oncology, Department of Anatomy and Cell Biology,University of Bergen, N-5009 Bergen, Norway

2 Address correspondence and reprint requests to Therese Visted, Department ofAnatomy and Cell Biology, University of Bergen 19, N-5019 Bergen, Norway.


  Abstract

Gene therapy using viral vectors has to date failed to reveal itsdefinitive clinical usefulness. Cell encapsulation technology represents analternative, nonviral approach for the delivery of biologically activecompounds to tumors. This strategy involves the use of genetically engineeredproducer cells that secrete a protein with therapeutic potential. The cellsare encapsulated in an immunoisolating material that makes them suitable fortransplantation. The capsules, or bioreactors, permit the release ofrecombinant proteins that may assert their effects in the tumormicroenvironment. During the last decades, there has been significant progressin the development of encapsulation technologies that comprise devices forboth macro- and microencapsulation. The polysaccharide alginate is the mostcommonly used material for cell encapsulation and is well tolerated by varioustissues. A wide spectrum of cells and tissues has been encapsulated andimplanted, both in animals and humans, indicating the general applicability ofthis approach for both research and medical purposes, including CNSmalignancies. Gliomas most frequently recur at the resection site. To providelocal and sustained drug delivery, the bioreactors can be implanted in thebrain parenchyma or in the ventricular system. The development ofcomprehensive analyses of geno- and phenotypic profiles of a tumor (genomicsand proteomics) may provide new and important guidelines for choosing theoptimal combination of bioreactors and recombinant proteins for therapeuticuse.

Received December 8, 2000; Accepted March 14, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
M. L. Willson, C. McElnea, J. Mariani, A. M. Lohof, and R. M. Sherrard
BDNF increases homotypic olivocerebellar reinnervation and associated fine motor and cognitive skill
Brain, April 1, 2008; 131(4): 1099 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Waxman and P. S. Schwartz
Harnessing Apoptosis for Improved Anticancer Gene Therapy
Cancer Res., December 15, 2003; 63(24): 8563 - 8572.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.